Custom service

Peptide Target Binder Development

Develop peptide binders to a target from design through validated affinity

Turnaround: 6–12 weeksTypical scale: 0.1 mg – 10 g per sequenceChemistry options: in-silico pre-screening; library or rational candidate generation; SPR/BLI affinity confirmation

Teams come to this service when they need to develop peptide binders to a target from design through validated affinity. We typically start from in-silico pre-screening, add library or rational candidate generation where the application demands it, and close the loop with SPR/BLI affinity confirmation so the final validated binder set with Kd data behaves consistently across lots.

Design reviews are part of the schedule, not an extra. Sequence, spacer architecture and analytical strategy are signed off before the first synthesis run, which is why the 6–12 weeks timeline holds in practice.

Affinity maturation of weak starting hits

Binders for assay capture and blocking

Binder development against impure or unstable targets

Sequences where a recombinant expression route is objectively cheaper and faster

Release specification is fixed at quotation: standard >95% by HPLC, >98% for assay-critical material. Long chains (>60 residues) are additionally confirmed by MS/MS sequence coverage, and truncated-deletion species are quantified, not just summarized.

Service Highlights

  • In-silico pre-screening as the default route, with library or rational candidate generation held as a proven fallback
  • SPR/BLI affinity confirmation worked into the design where the application requires it
  • Sequence difficulty analysis (aggregation risk, motif hazards) is done before synthesis, and the route is chosen around it
  • Analytical confirmation of every intermediate before the final release
  • Microwave-assisted coupling and double-coupling are applied automatically where the sequence demands them
  • Validated binder set with Kd data delivered with a complete conjugation or synthesis certificate

How the work runs

  1. Sequence analysis

    Peptide Target Binder Development is analyzed for aggregation risk, motif hazards and puri?cation difficulty before a route is quoted.

  2. Route selection

    Fmoc solid-phase, fragment ligation or hybrid solution-phase is selected and documented.

  3. Assembly

    The chain is built with in-silico pre-screening applied where the sequence demands it, with double-coupling at hazard sites.

  4. Cleavage & crude QC

    Crude material is characterized so purification targets are set on data, not hope.

  5. Purification

    RP-HPLC (and ion-exchange where needed) delivers the agreed purity; fractions are pooled on MS confirmation.

  6. Release

    Validated binder set with Kd data is documented with the full analytical package and released.

Specifications & timeline

Turnaround
6–12 weeks
Typical scale
0.1 mg – 10 g per sequence
Chemistry options
in-silico pre-screening; library or rational candidate generation; SPR/BLI affinity confirmation
Deliverable
Validated binder set with Kd data
QC package
HPLC purity, ESI/MALDI MS, MS/MS confirmation for long chains
Shipping
Ambient with desiccant; blue ice for modified or sensitive peptides

Related Products

Next step

Tell us the target, we will tell you what is feasible

Send the sequence, assay format and sensitivity you need. You will get a technical assessment — recommended platform, timeline and the risks worth knowing before you commit budget.